Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Arnulf, Bertrand

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. [electronic resource] - Haematologica Dec 2012 - 1925-8 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1592-8721

10.3324/haematol.2012.067793 doi


Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Boronic Acids--therapeutic use
Bortezomib
Female
Follow-Up Studies
Humans
Injections, Intravenous
Injections, Subcutaneous
Male
Multiple Myeloma--drug therapy
Neoplasm Recurrence, Local--drug therapy
Prognosis
Pyrazines--therapeutic use
Remission Induction
Survival Rate